Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 3:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuroprotective Clear all
Withdrawn Phase 1 Interventional

Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention

NCT05032781
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Intra-arterial cold saline, minocycline, and magnesium
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Neuroprotection in Acute Ischemic Stroke

NCT03320018
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Hydrogen, Minocycline, Placebo Hydrogen, Placebo Minocycline
Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Jun 25, 2026, 3:05 PM EDT
Withdrawn Not applicable Interventional

Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - MHSB

NCT03673579
View directory record Official record
Conditions
Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less), Neonatal Infection, Satisfaction, Stress, Chronic Lung Disease, Growth Acceleration, Adverse Event
Interventions
NICU Dashboard
Device
Lead sponsor
Philips Healthcare
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
South Bend, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

NCT01188811
View directory record Official record
Conditions
Multiple Sclerosis, Chronic Progressive
Interventions
lipoic acid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Jun 25, 2026, 3:05 PM EDT
Terminated Not applicable Interventional Results available

Treatment of Subarachnoid Hemorrhage With Human Albumin

NCT00283400
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
25% human albumin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 79 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Hershey, Pennsylvania • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage

NCT02670824
View directory record Official record
Conditions
Intracerebral Hemorrhage (ICH)
Interventions
CN-105, Placebo
Drug
Lead sponsor
AegisCN LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Phase 3 Interventional

Clinical Trial of Memantine for Major Depression

NCT00040261
View directory record Official record
Conditions
Depression
Interventions
Memantine HCL
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 25, 2026, 3:05 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

NCT00267007
View directory record Official record
Conditions
Peripheral Neuropathy, Chemotherapy-induced
Interventions
PROCRIT 40,000 IU QW, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Results available

Safety of Polyphenon E in Multiple Sclerosis Pilot Study

NCT00836719
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Polyphenon E
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke

NCT00630396
View directory record Official record
Conditions
Stroke, Acute
Interventions
Minocycline
Drug
Lead sponsor
David Hess, MD
Other
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Lexington, Kentucky • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Phase 2 Interventional Results available

Lipoic Acid for Progressive Multiple Sclerosis (MS)

NCT03161028
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Lipoic acid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jun 25, 2026, 3:05 PM EDT
Withdrawn Phase 2 Interventional

Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis

NCT02011451
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
95% Pure ECGC capsules 200mg, Placebo Comparator:
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Jun 25, 2026, 3:05 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II

NCT01451723
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Polyphenon E, Placebo
Drug · Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Jun 25, 2026, 3:05 PM EDT
Recruiting Early Phase 1 Interventional

Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia

NCT02621944
View directory record Official record
Conditions
Hypoxic Ischemic Encephalopathy
Interventions
Melatonin, Magnetic Resonance Imaging, Pharmacokinetics, Neurological Outcome Assessment
Drug · Other · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
Up to 6 Hours
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jun 25, 2026, 3:05 PM EDT
Withdrawn Not applicable Interventional

Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO

NCT03673566
View directory record Official record
Conditions
Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less), Neonatal Infection, Satisfaction, Stress, Chronic Lung Disease, Growth Acceleration, Adverse Event
Interventions
NICU Dashboard
Device
Lead sponsor
Philips Healthcare
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Not applicable Interventional

A Study of Decreased Mental Function Associated With HIV

NCT00027040
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Selegiline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Phase 2 Interventional

Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

NCT05585606
View directory record Official record
Conditions
Acute Ischemic Stroke (AIS)
Interventions
Placebo, scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg), scp776 (all dose levels)
Drug
Lead sponsor
Silver Creek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Scottsdale, Arizona • Tucson, Arizona • Hartford, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jun 25, 2026, 3:05 PM EDT
Suspended Early Phase 1 Interventional

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

NCT06171152
View directory record Official record
Conditions
Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
Interventions
Liraglutide Pen Injector [Saxenda], Medication Diary
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 25, 2026, 3:05 PM EDT
Terminated Phase 2 Interventional Results available

Atacicept in Subjects With Optic Neuritis

NCT00624468
View directory record Official record
Conditions
Optic Neuritis
Interventions
Atacicept, Placebo matched to atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Fairfield, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Not applicable Interventional

The ParkCycle Study: Aerobic Exercise in PD

NCT01562496
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Exercise
Behavioral
Lead sponsor
Radboud University Medical Center
Other
Eligibility
30 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes

NCT00591006
View directory record Official record
Conditions
Healthy
Interventions
Phenytoin (brand name Dilantin), Hydrocortisone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Phase 2 Interventional Results available

Parkinson's Disease Isradipine Safety Study

NCT00753636
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Dynacirc CR (Isradipine)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Jun 25, 2026, 3:05 PM EDT
Completed Phase 3 Interventional Results available

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

NCT03169881
View directory record Official record
Conditions
Neurocognitive, Neuroprotective, Neonatal, Neurodevelopmental Impairment
Interventions
Darbepoetin, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
1 Hour to 24 Hours
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jun 25, 2026, 3:05 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke

NCT00893867
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
DP-b99, Placebo
Drug
Lead sponsor
D-Pharm Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
13
States / cities
Oceanside, California • Danbury, Connecticut • Savannah, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Jun 25, 2026, 3:05 PM EDT